Adenylosuccinate Is an Insulin Secretagogue Derived from Glucose-Induced Purine Metabolism

•Glucose stimulation increases the levels of adenylosuccinate (S-AMP) in β cells•Interfering with S-AMP synthesis impairs glucose-stimulated insulin secretion•Addition of S-AMP to patch-clamped human β cells stimulates insulin exocytosis•S-AMP rescues secretory function in β cells from a human with type 2 diabetes

SummaryPancreatic islet failure, involving loss of glucose-stimulated insulin secretion (GSIS) from islet β cells, heralds the onset of type 2 diabetes (T2D). To search for mediators of GSIS, we performed metabolomics profiling of the insulinoma cell line 832/13 and uncovered significant glucose-induced changes in purine pathway intermediates, including a decrease in inosine monophosphate (IMP) and an increase in adenylosuccinate (S-AMP), suggesting a regulatory role for the enzyme that links the two metabolites, adenylosuccinate synthase (ADSS). Inhibition of ADSS or a more proximal enzyme in the S-AMP biosynthesis pathway, adenylosuccinate lyase, lowers S-AMP levels and impairs GSIS. Addition of S-AMP to the interior of patch-clamped human β cells amplifies exocytosis, an effect dependent upon expression of sentrin/SUMO-specific protease 1 (SENP1). S-AMP also overcomes the defect in glucose-induced exocytosis in β cells from a human donor with T2D. S-AMP is, thus, an insulin secretagogue capable of reversing β cell dysfunction in T2D.

Graphical AbstractFigure optionsDownload full-size imageDownload as PowerPoint slide